News archive


altona Diagnostics developed the RealStar® Zika Virus RT-PCR Kit 1.0 for the qualitative detection of Zika virus specific RNA. The in vitro diagnostic test is based on real-time reverse transcriptase/polymerase chain reaction (RT-PCR) technology and contains an Internal Control for reliable diagnostics.


The RealStar® MERS-CoV RT-PCR Kit U.S. is a real-time reverse transcriptase polymerase chain reaction (rRT-PCR) test for the in vitro qualitative detection of RNA from MERS-CoV in lower respiratory specimens (tracheal aspirate/tracheal secretions) from individuals with signs and symptoms of infection with MERS-CoV in conjunction with epidemiological risk factors. The RealStar® MERS-CoV RT-PCR Kit U.S. consists of two independent assays, one targeting a region upstream of the E gene (upE) and the other targeting open reading frame 1a (orf1a) of the MERS-CoV genome.  Both assays include a heterologous amplification system (Internal Control) to identify possible RT-PCR inhibition and to confirm the integrity of the reagents of the kit.


We would like to comment on the article by Broadhurst et al. The authors compared the ReEBOV Antigen Rapid Test Kit (Corgenix Inc) with the RealStar® Filovirus Screen RT-PCR Kit 1.0 (altona Diagnostics GmbH) and an in-house developed real-time RT-PCR method referred to as Trombley-assay.


The RealStar® Influenza S&T RT-PCR Kit 3.0 and the RealStar® Influenza RT-PCR Kit 1.0 facilitate the detection of the drifted influenza A (H3N2) viruses circulating as dominant subtype in the 2014/15 influenza season in Europe:


The RealStar® Ebolavirus RT-PCR Kit 1.0 is a real-time reverse transcription polymerase chain reaction (RT-PCR) test intended for WHO has accepted the first Ebola in vitro diagnostic for procurement by United Nations and other partners to Ebola affected countries. The product, RealStar® Filovirus Screen RT-PCR Kit 1.0 manufactured by Altona Diagnostics GmbH, was assessed under an emergency quality assessment mechanism established by WHO to address the lack of Ebola tests, and to fast-track countries’ access to reliable testing options.